Skip to main content

Table 1 LRIG1 copy number ratios and clinicopathological characteristics of the breast cancer cohort

From: LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer

Characteristic

Lossa

Normala

Gaina

P-value*

Number of patients (N = 423

77 (18.2%)

293 (69.3%)

53 (12.5%)

 

Age at diagnosis (years; mean ± SD)

55.7 ± 13.3

60.1 ± 11.54

62.5 ± 13.42

 

Age ≤ 60 (N = 211)

46 (21.8%)

142 (67.3%)

23 (10.9%)

0.125

Age > 60 (N = 212)

31 (14.6%)

151 (71.2%)

30 (14.2%)

 

Steroid receptor status

<  0.001

 Negative (N = 117)

39 (33.3%)

65 (55.6%)

13 (11.1%)

 

 Positive (N = 306)

38 (12.4%)

228 (74.5%)

40 (13.1%)

 

ERBB2status

0.002

 Negative (N = 336)

50 (14.9%)

245 (72.9%)

41 (12.2%)

 

 Positive (N = 87)

27 (31.0%)

48 (55.2%)

12 (13.8%)

 

Tumor subtype

< 0.001

ERBB2+, ER/PR- (N = 45)

16 (35.6%)

23 (51.1%)

6 (13.3%)

 

ERBB2+, ER/PR+ (N = 42)

11 (26.2%)

25 (59.5%)

6 (14.3%)

 

ERBB2-, ER/PR+ (N = 264)

27 (10.2%)

203 (76.9%)

34 (12.9%)

 

ERBB2-, ER/PR- (N = 72)

23 (31.9%)

42 (58.3%)

7 (9.7%)

 

Disease stage (N = 278; missing data = 145)

0.151

 I (N = 109)

18 (16.5%)

84 (77.1%)

7 (6.4%)

 

 II (N = 131)

28 (21.4%)

85 (64.9%)

18 (13.7%)

 

 III (N = 7)

1 (14.3%)

5 (71.4%)

1 (14.3%)

 

 IV (N = 31)

6 (19.4%)

17 (54.8%)

8 (25.8%)

 

Tumor grade (N = 363, missing data = 60)

0.004

 I (N = 31)

1 (3.2%)

25 (80.6%)

5 (16.1%)

 

 II (N = 137)

15 (10.9%)

104 (75.9%)

18 (13.1%)

 

 III (N = 195)

50 (25.6%)

120 (61.5%)

25 (12.8%)

 

Tumor size (N = 329, missing data = 94)

0.158

 Size ≤20 mm (N = 154)

29 (18.8%)

111 (72.1%)

14 (9.1%)

 

 Size > 20 mm (N = 175)

37 (21.1%)

111 (63.4%)

27 (15.4%)

 

Nodal status (N = 360, missing data = 63)

0.001

 Negative (N = 279)

43 (15.4%)

207 (74.2%)

29 (10.4%)

 

 Positive (N = 81)

24 (29.6%)

43 (53.1%)

14 (17.3%)

 

Tumor types

0.041

 Ductal (N = 354)

66 (18.6%)

237 (66.9%)

51 (14.4%)

 

 Lobular (N = 35)

5 (14.3%)

30 (85.7%)

0 (0.0%)

 

 Others (N = 34)

6 (17.6%)

26 (76.5%)

2 (5.9%)

 
  1. aLRIG1/CYP1B1 ratio < 0.85, loss; 0.85–1.15, normal; > 1.15, gain
  2. *The overall P values are from comparisons between all LRIG1 loss, LRIG1 normal and LRIG1 gain groups. Significance was calculated by the 2-sided Fisher’s exact test